

The Academy for Clinical Debates & Controversies in Medicine




# CHEP

## 2<sup>ND</sup> WORLD CONGRESS ON **CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS**



BERLIN, GERMANY • OCTOBER 18-20, 2012

## **1<sup>ST</sup> ANNOUNCEMENT AND CALL FOR ABSTRACTS**



[www.comtecmed.com/chep](http://www.comtecmed.com/chep) • [chep@comtecmed.com](mailto:chep@comtecmed.com)





2<sup>ND</sup> WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS  
BERLIN, GERMANY • OCTOBER 18-20, 2012

## Dear Friends and Colleagues,

Following the success of the **1<sup>st</sup> World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)**, we are very pleased to invite you to participate in the **2<sup>nd</sup> C-Hep Congress** which will be held in Berlin, Germany on October 18-20, 2012.

The large attendance and enthusiastic feedback of the 1<sup>st</sup> Congress held last May in Barcelona highlighted the need for such a meeting focusing on the needs of the busy clinician caring for HCV and HBV infected patients. The C-Hep Congress attempts to summarize all the key new data recently presented – and how it might be implemented in routine care of Hepatitis B and C patients. Overviews, state of the art lectures and controversial debates with the outstanding faculty of prominent world leaders presenting both pro and con positions challenge and explore the optimal treatment for patients, including the appropriate use of new drugs. This educational Congress focuses on clinical practices in Viral Hepatitis and benefits not only Hepatologists and Infectious Diseases specialist, but also general practitioners, internists and primary care physicians with a desire to gain knowledge in these exciting advances.

The format includes a significant allocation of time for interactive debates and questions from the audience to each panel of experts. Participants are encouraged to take an active role in the discussions with faculty members which follow each debate, in a unique and open environment.

We look forward to welcoming you at the **2<sup>nd</sup> C-Hep Congress** in the lovely city of Berlin.

Sincerely,

**Jürgen Rockstroh, MD**  
Germany

**Jonathan M. Schapiro, MD**  
Israel

*Co-Chairpersons*





2<sup>ND</sup> WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS  
BERLIN, GERMANY • OCTOBER 18-20, 2012

## PRELIMINARY SCIENTIFIC PROGRAM

### THURSDAY, OCTOBER 18, 2012

#### HALL A

<b>14:00-16:00</b>	<b>PLENARY SESSION 1</b> Moderators: <b>Jürgen Rockstroh</b> , <i>Germany</i> ; <b>Jonathan Shapiro</b> , <i>Israel</i>
14:00-14:05	Chairpersons Congress Welcome Address
14:05-14:30	HCV in 2020: Any cases left? <b>Rafael Esteban</b> , <i>Spain</i>
14:30-14:35	Discussion
14:35-15:00	HCV vaccine: Where do we stand? <b>Ulrich Spengler</b> , <i>Germany</i>
15:00-15:05	Discussion
15:05-15:25	Interferon-free HCV therapy: Are we getting there? No: <b>Graham Foster</b> , <i>UK</i>
15:25-15:45	Yes: <b>Heiner Wedemeyer</b> , <i>Germany</i>
15:45-16:00	Discussion
<b>16:00-17:00</b>	TBA
<b>17:00-17:30</b>	<i>Coffee Break and Poster Exhibition</i>
<b>17:30-18:45</b>	TBA
<b>18:45-20:00</b>	<b>Welcome Reception and Poster Prize Ceremony</b>

### FRIDAY, OCTOBER 19, 2012

#### HALL A

<b>09:00-11:00</b>	<b>PLENARY SESSION 2</b> Moderators: <b>Stefan Zeuzem</b> , <i>Germany</i> ; <b>Eckhard Schott</b> , <i>Germany</i>
09:00-09:05	Overview of HCV sessions by HCV Program Director <b>Stefan Zeuzem</b> , <i>Germany</i>
09:05-09:10	Direct Antivirals: How have the treatment paradigms changed? Moderators Introduction
09:10-09:30	HCV Direct Acting Antivirals: In treatment naïve: <b>Stanislas Pol</b> , <i>France</i>
09:30-09:50	In treatment experienced: <b>Thomas Berg</b> , <i>Germany</i>
09:50-10:10	Toxicity management: <b>Christoph Hezode</b> , <i>Paris</i>
10:10-10:40	Drug-drug interactions: <b>David Back</b> , <i>UK</i>
10:40-11:00	Panel discussion
<b>11:00-11:30</b>	<i>Coffee Break</i>



2<sup>ND</sup> WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS  
BERLIN, GERMANY • OCTOBER 18-20, 2012

## PRELIMINARY SCIENTIFIC PROGRAM

### FRIDAY, OCTOBER 19, 2012

#### HALL A

- 11:30-12:15** **SESSION 3**  
Do we need to know genetic factors such as IL28B for treatment decision making?  
11:30-11:45 Yes: **Vincent Soriano, Spain**  
11:45-12:00 No: **Mathew Albert, France**  
12:00-12:15 Discussion

**12:15-13:00** *Lunch Break*

**13:00-14:15** TBA

- 14:15-15:00** **SESSION 5**  
Patients should wait for DAA combination therapy  
14:15-14:30 Yes: **Patrick Ingiliz, Germany**  
14:30-14:45 No: **Geoffrey Dusheiko, UK**  
14:45-15:00 Discussion

- 15:00-15:30** **SESSION 7**  
INTERACTIVE CASE SESSION  
How to treat HCV relapse after OLTX  
**Raffaele Bruno, Italy**

**15:30-16:00** *Coffee Break*

#### HALL A

- 16:00-17:30** **PLENARY SESSION 9**  
16:00-16:20 Fatty liver disease: What do we know?  
**Douglas Dieterich, USA**  
16:20-16:40 Vitamin D and liver disease: Which role does it play?  
**Christian M. Lange, Switzerland**  
16:40-17:00 End-stage liver disease: What is new?  
**Marion Peters, USA**  
17:00-17:20 Treatment of HCC: State of the Art  
**Massimo Puoti, Italy**  
17:20-17:30 Panel Discussion

#### HALL B

- SESSION 4**  
HCV therapy is for specialists only?  
Yes: **Marion Peters, USA**  
No: **Michael Biermer, Germany**  
Discussion

- SESSION 6**  
Resistance to HCV Protease Inhibitors: Game over?  
Yes: **Jean Michel Pawlotsky, France**  
No: **Christoph Sarrazin, Germany**  
Discussion

- SESSION 8**  
INTERACTIVE CASE SESSION  
How to treat HCV in HIV coinfection  
**Stefan Mauss, Germany**



2<sup>ND</sup> WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS  
BERLIN, GERMANY • OCTOBER 18-20, 2012

## PRELIMINARY SCIENTIFIC PROGRAM

**SATURDAY, OCTOBER 20, 2012**

**HALL A**

- 08:30-10:30** **PLENARY SESSION 10**  
HBV THERAPY IN 2012  
Moderators: **Fabien Zoulim**, *France*; **Jörg Petersen**, *Germany*
- 08:30-08:35 Overview of HBV sessions by HBV Program Director  
**Fabien Zoulim**, *France*
- 08:35-09:00 Hepatitis B Therapy: State of the Art and open challenges  
**Jörg Petersen**, *Germany*
- 09:00-09:15 Is there a need for combination therapy?  
Yes: **Florian van Boemmel**, *Germany*  
09:15-09:30 No: **Maria Buti**, *Spain*
- 09:30-09:50 HBV preventive and therapeutic vaccines: What is new?  
**Marie-Louise Michel**, *France*
- 09:50-10:10 Hepatitis Delta: What is new?  
**Heiner Wedemeyer**, *Germany*
- 10:10-10:30 Panel Discussion
- 10:30-11:00** *Coffee Break*
- 11:00-11:45** **PLENARY SESSION 11**  
INTERACTIVE CASE SESSION  
Moderator: **Fabien Zoulim**, *France*  
The challenging hepatitis B case  
**Mark Nelson**, *UK*  
**Karine Lacombe**, *France*
- 11:45-12:45** **PLENARY SESSION 12**
- 11:45-12:00 Strategies to prevent HCC: What can we do?  
**Mark Thursz**, *UK*
- 12:00-12:15 Can we afford HCV DAAs for all?  
**Maud Lemoine**, *France*
- 12:15-12:45 What are the remaining challenges in hepatitis research?  
**Michael Manns**, *Germany*





# C-HEP

## 2<sup>ND</sup> WORLD CONGRESS ON CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS

BERLIN, GERMANY • OCTOBER 18-20, 2012

### THE C-HEP YOUNG INVESTIGATOR POSTER AWARD

We are delighted to announce a special opportunity for young investigators. The C-Hep Young Investigator Poster Exhibition will be held during the C-Hep Congress.

**An award will be granted to the winning author. Posters will be evaluated by the C-Hep Awards Committee. First prize will receive 500 Euros and the two runners-up will receive free registration to the 2013 C-Hep conference.**

THE DEADLINE FOR ABSTRACTS SUBMISSION IS:

**AUGUST 6, 2012**

## GENERAL INFORMATION

### REGISTRATION

	Early Registration Until August 6, 2012	Late Registration from August 7 until October 9, 2012	From October 10, 2012 and On Site
Participants - Physicians and Scientists	€540	€590	€650
Residents, Nurses, Students	€385	€430	€470

\* Note: American Express and Diners Credit card payments (only) will be charged to your account in US\$ according to the rate of exchange to the Euro on the date of payment, all other credit cards will be charged to your account in Euro.

Registration fees include: Participation in scientific sessions, Congress bag, program book, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday.

### LIABILITY

The Congress Secretariat and Organizers cannot accept liability for personal accidents, nor loss of or damage to private property of participants, either during or directly arising from the 2<sup>nd</sup> World Congress on Controversies in the Management of Viral Hepatitis (C-Hep). Participants should make their own arrangements with respect to health and travel insurance.

### CONGRESS SECRETARIAT

Please do not hesitate to contact the Secretariat if you require any additional information or assistance. Please address all correspondence to: [chep@comtecmed.com](mailto:chep@comtecmed.com)



#### Headquarters and Administration:

53 Rothschild Boulevard  
PO Box 68  
Tel Aviv 61000, Israel  
Tel: +972-3-5666166  
Fax: +972-3-5666177  
Email: [info@comtecmed.com](mailto:info@comtecmed.com)

#### Comtec Spain:

Bailén, 95-97  
pral. 1. a - 08009  
Barcelona, Spain  
Tel: +34-93-2081145  
Fax: +34-93-4579291  
Email: [spain@comtecmed.com](mailto:spain@comtecmed.com)

#### Comtec China:

175 Xiang Yang Road South  
Shanghai 200031  
China  
Tel: +86-21-54660460  
Fax: +86-21-54660450  
Email: [china@comtecmed.com](mailto:china@comtecmed.com)

[www.comtecmed.com/chep](http://www.comtecmed.com/chep) • [chep@comtecmed.com](mailto:chep@comtecmed.com)